This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cabergoline Reduces OHSS

This study has been completed.
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier:
First received: February 23, 2007
Last updated: February 26, 2007
Last verified: February 2007
The present study was designed to provide clinical confirmation of Cb2’s value as a new approach in the prevention of increased vascular permeability and hemoconcentration, both signs of OHSS in humans, and in order to explore its mechanism of action. To this end, a prospective, randomized, placebo-controlled study was designed in which Cb2 was employed in women at risk of OHSS after gonadotropin administration for ART. Simultaneously, ovarian perfusion was assessed in these patients using MR pharmacokinetic modeling.

Condition Intervention Phase
Ovarian Hyperstimulation Syndrome Drug: Cabergoline Procedure: MR Procedure: Ultrasound Procedure: Blood Analysis Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction.

Resource links provided by NLM:

Further study details as provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:

Estimated Enrollment: 60
Study Start Date: April 2004
Estimated Study Completion Date: July 2006
  Show Detailed Description


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 - 35 years old healthy women, with risk of developing OHSS.

Exclusion Criteria:

  • No risk of developing OHSS; < 20 oocytes retrieved.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440258

Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
Study Director: Antonio Pellicer, MD IVI VALENCIA
  More Information Identifier: NCT00440258     History of Changes
Other Study ID Numbers: VLC-AP-404-207-1
Study First Received: February 23, 2007
Last Updated: February 26, 2007

Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
Ovarian hyperstimulation syndrome, dopamine agonists, cabergoline, hemoconcentration, ascites, ovarian perfusion, dopamine receptor 2

Additional relevant MeSH terms:
Ovarian Hyperstimulation Syndrome
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Dopamine Agonists
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents processed this record on September 21, 2017